However, people involved with the offering argue that the companyÆs fast growth rate, its focus on the elderly as its primary patient group its flagship drug is used to treat osteoporosis, and the inclusion two years ago of that drug into ChinaÆs national insurance programme should make this an interesting stock for international investors keen to...
¬ Haymarket Media Limited. All rights reserved.
